Italian medical laboratory Gruppo Centro Servizi Medici (CSM) has installed the SOPHiA DDM Platform developed by software company Sophia Genetics.

The SOPHiA DDM Platform is used by hospitals, laboratories and biopharmaceutical institutions worldwide to analyse complex multimodal data sets and different diagnostic modalities.

Using the cloud-native platform, CSM aims to expand its next-generation sequencing (NGS) capabilities and support its research into hereditary cancer and homologous recombination deficiency.

The laboratory intends to use the platform to improve the detection and categorisation of hereditary cancers, as well as help clinical researchers identify genomic profiles that respond effectively to specific therapies.

SOPHiA GENETICS managing director Kevin Puylaert said: “It is our goal to democratise data-driven medicine, and the enhanced testing offered by CSM will help enable that in Italy.

“By using the SOPHiA DDM Platform, CSM will have unified data across all access points, increasing the ease with which these sites can share data, communicate and deliver genomic analyses.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The platform uses artificial intelligence (AI) and patented technologies to examine and interpret NGS data.

According to SOPHiA GENETICS, it enables a more efficient bioinformatics workflow and will provide CSM with in-house ownership of genomic databases shared across its access points.

This is intended to translate into quicker data interpretation and expedited delivery of results.

CSM carries out more than one million exams a year, providing around 1,500 types of tests.

Last week, Centre Hospitalier de Bastia in Corsica began using SOPHiA GENETICS’ SOPHiA DDM Platform.

The platform is intended to allow the hospital to introduce in-house NGS and support its clinical oncology research, particularly in the field of haematologic malignancies.

Centre Hospitalier de Bastia’s work with SOPHiA DDM will focus on haematologic cancers such as leukaemia and lymphoma, as the platform could help categorise disease-associated mutations and provide deeper insights.